Pleased to share our newly published Brief Practice Update and Consensus Statement from the Society of Vascular and Interventional Neurology on intracranial atherosclerotic disease related large vessel occlusion (ICAS-LVO).
@samialkasab@alex_spiotta
https://t.co/sk31XVAggr
Nice RCT of 300 acute LVO patients with low NIHSS 1–5, a small core, and a large penumbra randomized to thrombectomy versus best medical within 24 hours of onset.
Rate of good outcome MRS 0–1 at 90 days:
Thrombectomy: 69%
Best medical: 50%
Trial of Endovascular Therapy for Mild Stroke with Large-Vessel Occlusion
@NEJM
https://t.co/UmxRn6ZuKb
Mild symptoms or late arrival need not close the door to thrombectomy.
Two NEJM trials highlight the value of imaging selection:
🧠 MILD-MT: NIHSS <6, ≤24 h, core ≤50 mL and mismatch ≥50 mL. EVT improved 90-day mRS 0–1: 69.4% vs 50.0% (NNT 6). Symptomatic ICH: 2.1% vs 1.9%; serious procedural complications: 13.2%.
⏱️ LATE-MT: Selected LVO patients presenting 24–72 h benefited functionally (common OR 1.74), but symptomatic ICH was 4.8% vs 0% and mortality 6.0% vs 1.8%.
Assess the vessel and salvageable tissue—not NIHSS or clock alone. Selection and procedural risk matter.
NEJM references:
MILD-MT: https://t.co/qKFQeKpKy8
LATE-MT: https://t.co/LJEfCuWwDd
#Stroke #Thrombectomy #Neuroradiology
🧠 USMS Autumn Stroke School 2026 took place in Poltava, Ukraine, on 12–16 October, endorsed by @ESOstroke!
👥 36 participants | 🎙️ 26 speakers
📚 55 lectures | 🩺 2 masterclasses
📋 20+ clinical cases
Together, we’re building better stroke care in Ukraine! 🇺🇦
#StrokeCare
🧠💉The RESILIENT-Extend trial will examine whether mechanical thrombectomy improves functional outcome over best medical therapy alone in the 8-24h window using a simple imaging strategy
Read more here👇
https://t.co/5ksyck4NDL
You can still register for the joint ESMINT–ESO Webinar for expert perspectives on key discussions and developments in neurointervention & stroke medicine from #ESMINT2026.
🔗 Register: https://t.co/4mjPskdkkU
📅 21 Sept
🕔 17:00 CEST
💬 Live Q&A
#Stroke@esmintsociety
🧠 August Newsletter
New 🆕 Acute Stroke Imaging Masterclass
📚 Upcoming webinars
🎓 Past webinar on SCD-KIDS
📄 Paper of the Month: Stroke Rehabilitation
🎙️ From Paper to Practice Ep. 9
💡 #MondayTips with Dr. Rodrigo Guerrero
Read the full newsletter 👇
https://t.co/aZJJ1wuZho
🚨Don’t miss our upcoming webinar on 𝐂𝐚𝐫𝐨𝐭𝐢𝐝 𝐚𝐧𝐝 𝐕𝐞𝐫𝐭𝐞𝐛𝐫𝐚𝐥 𝐀𝐫𝐭𝐞𝐫𝐲 𝐃𝐢𝐬𝐞𝐚𝐬𝐞
📅Date: 3 September 2026
Part of the @WorldStrokeOrg Neurointerventional Fellowship series with Dr. @InoaVioliza
👉Register: https://t.co/aTXYBXV9sY
#StrokeEducation
Carotid Revascularization in the Era of Modern Medical Therapy: Is Urgency Still Justified? | Stroke: Vascular and Interventional Neurology https://t.co/CR5nFnJWlQ
⏰ Final call for the 2026 ESMINT e-Fellowship Programme!
Learn from leading experts, observe live procedures and interact with treating physicians in real time.
📅 Apply by 19 August, 23:59 CEST.
🔗 https://t.co/nBWNBybUmS
#ESMINT#EFellowship#Neurointervention
#MondayTip#Early ticagrelor+aspirin after IV thrombolysis may improve 90-day excellent recovery in selected moderate AIS (NIHSS 4–10)
🚶��♀️mRS 0–1 68.7% vs 62.0%
🩸sICH was rare, but CIs were wide.
☝️Defined phenotype, not broad adoption yet
#TAPIS
🔗https://t.co/OtcXjSKkFF
🧠⚖️ Dr. Emanuel Orru focused discussion on key controversies shaping modern mechanical thrombectomy practice.
📊 Included discussion of the ORIENTAL MEVO trial, adding to evolving evidence in medium vessel occlusions (MEVO), where the true magnitude of benefit and ideal patient selection remain uncertain.
🧠 ASPECTS ≤2 / large-core stroke Emerging trial data suggest possible benefit in carefully selected patients, but outcomes remain heterogeneous. This continues to be one of the most debated frontiers in EVT, particularly regarding functional recovery vs procedural risk in very large infarcts.
🛠️ Technical considerations in EVT expansion As thrombectomy extends into more distal territories (MEVOs), key challenges include device selection, procedural safety, and the persistent gap between angiographic success and meaningful clinical outcomes.
#Stroke #Thrombectomy #MEVO #Neurology #Endovascular #MissionThrombectomy
📢 Now available: The #ESOC2026 Best of Neurointervention and Best of Secondary Prevention.
A valuable resource to share with your colleagues throughout the year.
👉 Neurointervention: https://t.co/ftfTcZ4S1l
👉 Secondary Prevention: https://t.co/VLTeqmicxn
#VoiceOfStroke
🎉 Meet the 2026–2028 ESO Emerging Leaders!
🔹 Irene Scala (Milan, Italy)
🔹 Aikaterini Theodorou (Athens, Greece)
🔹 @DHrynykha (Kyiv, Ukraine)
The application period for the Emerging Leader Programme is now open until 31 August 2026.
👉 https://t.co/Oztd8qQ5O8
#ESOC2026
#MondayTip#Tenecteplase may help—even when the artery stays closed.
In #TRACE3 (4.5–24h window), pts without recanalization still had better outcomes (42% vs 30%). Strongest effect in NIHSS ≥10.
👉 Think beyond large vessel reopening
https://t.co/T4nThkZR2D